![Alex Virgilio](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alex Virgilio
Analyst-Equity chez
Integral Health Asset Management LLC
Profil
Dr. Alex A. Virgilio is a Senior Analyst at Integral Health Asset Management LLC.
He has over 17 years of experience investing in private and public stage biotechnology companies, and an additional 8 years of experience working as a scientist or in business development at such companies.
Dr. Virgilio began his career as a Medicinal Chemist, first at Amgen, and then at a venture-backed startup.
He then worked in venture capital at FrazierHealthcare Ventures, and later returned to Amgen to assume a business development role.
At Amgen, he provided evaluations of numerous products and companies, several of which led to transactions.
Dr. Virgilio transitioned to an investment role in 2007 at PFM Health Sciences (fka PFM) where he spent 12 years of his investment career (2007-2019).
After retiring from PFM, he joined a former PFM colleague at Asymmetry Capital Management in late 2019.
In early 2022, Asymmetry returned capital to investors and the entire investment team joined Balyasny Asset Management.
He left Balyasny in September of 2022 and started with Integral in April 2023.
Dr. Virgilio received a BS from MIT, a PhD in chemistry from the University of California at Berkeley, and an MBA from the University of Michigan.
Postes actifs de Alex Virgilio
| Sociétés | Poste | Début |
|---|---|---|
Integral Health Asset Management LLC
 Integral Health Asset Management LLC Investment ManagersFinance IHAM seeks to achieve superior returns by investing in healthcare equity securities, which the firm deems to have significant appreciation potential over a medium to longer-term time horizon. They employ an investment strategy designed to produce a consistent absolute return profile with low volatility and little correlation to the broader market. IHAM conducts rigorous bottom-up fundamental analysis to discern relative winners and losers. The methodology generally favors thematic, relative value investing versus tactical, event driven trades. | Analyst-Equity | 01/04/2023 |
Anciens postes connus de Alex Virgilio
| Sociétés | Poste | Fin |
|---|---|---|
Balyasny Asset Management LP
 Balyasny Asset Management LP Investment ManagersFinance BAM aims to deliver consistent, uncorrelated absolute returns in all market environments. The firm manages multi-strategy investment funds which maintain a concentrated private equity portfolio. Their investment advisory services reflect a blend of strategies including fundamental long/short equity, macro & rates, systematic trading and event & credit investing. BAM’s long/short equity and equity trading strategies include (but are not limited to) investments and trading in the following market sectors: Energy, Health Care, Financials, Industrials, Information Technology, Consumer Staples and Consumer Discretionary. | Gestionnaire de Portefeuille-Actions | 01/09/2022 |
Asymmetry Capital Management LP
 Asymmetry Capital Management LP Investment ManagersFinance Asymmetry Capital Management seeks to deliver absolute, risk-adjusted returns across market cycles by investing in a value-oriented, diversified, global portfolio of healthcare companies. The firm's objective is to generate returns on both long and short positions with moderate to low net exposure and low correlations to broad equity and healthcare-related indices. Asymmetry also focuses on maximizing positive and sustainable impacts on ESG (environment, social and governance) and responsible investing. | Analyst-Equity | 01/05/2022 |
PFM Health Sciences LP
 PFM Health Sciences LP Investment ManagersFinance PFM generally uses bottom-up analysis in an attempt to identify transformational changes, trends, investment themes and core investment opportunities across asset classes and geographies. Their investment strategies are currently (1) Healthcare, which primarily invests in the global healthcare industry, (2) Growth Equity, which primarily invests in growth equity healthcare investments and (3) Biotech Opportunities, which primarily invests in biotech investments. The firm utilizes certain co-investment vehicles from time to time for investment opportunities in privately held companies. | Analyst-Equity | 01/01/2019 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2007 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2000 |
Formation de Alex Virgilio
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Balyasny Asset Management LP
Balyasny Asset Management LP Investment ManagersFinance BAM aims to deliver consistent, uncorrelated absolute returns in all market environments. The firm manages multi-strategy investment funds which maintain a concentrated private equity portfolio. Their investment advisory services reflect a blend of strategies including fundamental long/short equity, macro & rates, systematic trading and event & credit investing. BAM’s long/short equity and equity trading strategies include (but are not limited to) investments and trading in the following market sectors: Energy, Health Care, Financials, Industrials, Information Technology, Consumer Staples and Consumer Discretionary. | Finance |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
PFM Health Sciences LP
PFM Health Sciences LP Investment ManagersFinance PFM generally uses bottom-up analysis in an attempt to identify transformational changes, trends, investment themes and core investment opportunities across asset classes and geographies. Their investment strategies are currently (1) Healthcare, which primarily invests in the global healthcare industry, (2) Growth Equity, which primarily invests in growth equity healthcare investments and (3) Biotech Opportunities, which primarily invests in biotech investments. The firm utilizes certain co-investment vehicles from time to time for investment opportunities in privately held companies. | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Asymmetry Capital Management LP
Asymmetry Capital Management LP Investment ManagersFinance Asymmetry Capital Management seeks to deliver absolute, risk-adjusted returns across market cycles by investing in a value-oriented, diversified, global portfolio of healthcare companies. The firm's objective is to generate returns on both long and short positions with moderate to low net exposure and low correlations to broad equity and healthcare-related indices. Asymmetry also focuses on maximizing positive and sustainable impacts on ESG (environment, social and governance) and responsible investing. | Finance |
Integral Health Asset Management LLC
Integral Health Asset Management LLC Investment ManagersFinance IHAM seeks to achieve superior returns by investing in healthcare equity securities, which the firm deems to have significant appreciation potential over a medium to longer-term time horizon. They employ an investment strategy designed to produce a consistent absolute return profile with low volatility and little correlation to the broader market. IHAM conducts rigorous bottom-up fundamental analysis to discern relative winners and losers. The methodology generally favors thematic, relative value investing versus tactical, event driven trades. | Finance |
